15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $63M | $37M | 66.9% | -111.0% | — | $54M | $79M |
| 2024 | $58M | $21M | 63.8% | -191.4% | -$80M | $58M | $57M |
| 2023 | $85M | $31M | 72.9% | -168.4% | -$128M | $61M | $81M |
| 2022 | $76M | -$87M | 59.4% | -268.8% | -$182M | $92M | $178M |
| 2021 | $69M | -$65M | 53.4% | -274.1% | -$121M | $43M | $306M |
| 2020 | $46M | -$47M | 68.0% | -206.7% | -$86M | $52M | $233M |
| 2019 | $37M | -$40M | 71.2% | -302.5% | -$97M | $85M | $137M |
| 2018 | $27M | -$84M | 77.2% | -446.4% | -$106M | $84M | $66M |
| 2017 | $17M | -$67M | 78.8% | -520.7% | -$82M | $68M | $95M |
| 2016 | $16M | -$55M | 0.0% | -398.7% | -$52M | $30M | $105M |
| 2015 | $863000 | -$48M | 0.0% | -5855.3% | -$21M | $24M | $98M |
| 2014 | — | -$20M | — | — | — | $14M | $50M |
| 2014 | — | -$129M | — | — | — | — | $80M |
| 2013 | — | -$37M | — | — | -$30M | — | $100M |
| 2013 | — | -$112M | — | — | -$70M | — | $106M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $16M | $110M | 61.2% | -48.3% | — | $38M | $256M |
| Dec '25 | $16M | -$4M | 66.2% | -29.8% | — | $54M | $79M |
| Sep '25 | $18M | $6M | 67.4% | -38.6% | — | $48M | $86M |
| Jun '25 | $16M | $15M | 69.9% | -222.2% | — | $50M | $74M |
| Mar '25 | $13M | -$11M | 63.5% | -169.9% | — | $56M | $91M |
| Dec '24 | $15M | -$7M | 69.0% | -157.6% | — | $58M | $57M |
| Sep '24 | $15M | -$13M | 69.4% | -151.0% | — | $52M | $59M |
| Jun '24 | $15M | -$11M | 61.6% | -186.5% | — | $67M | $76M |
| Mar '24 | $13M | -$15M | 53.9% | -280.6% | — | $61M | $84M |
| Dec '23 | $20M | -$9M | 88.7% | -98.3% | — | $61M | $81M |
| Sep '23 | $35M | -$5M | 81.5% | -39.6% | — | $46M | $72M |
| Jun '23 | $17M | -$25M | 55.3% | -288.2% | — | $55M | $78M |
| Mar '23 | $12M | -$22M | 48.1% | -473.6% | — | $92M | $152M |
| Dec '22 | $16M | -$27M | 53.0% | -333.1% | — | $92M | $178M |
| Sep '22 | $17M | -$23M | 56.3% | -307.0% | — | $91M | $208M |
| Jun '22 | $19M | -$21M | 59.6% | -269.6% | — | $86M | $249M |
| Mar '22 | $24M | -$16M | 65.7% | -197.6% | — | $85M | $288M |
| Dec '21 | $18M | -$32M | 47.9% | -339.2% | — | $43M | $306M |
| Sep '21 | $21M | -$21M | 47.0% | -236.8% | — | $53M | $253M |
| Jun '21 | $18M | -$4M | 58.1% | -240.2% | — | $52M | $275M |
How the market has priced FBIOP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Fortress Biotech, Inc.'s revenue has grown 6.8% per year. These are computed facts, not advice.
As of FY2025, Fortress Biotech, Inc. reported $54M of total debt against $79M of cash.
In FY2025, gross margin was 66.9%, operating margin -111.0%, and net margin 58.5%.
As of Jun '26, Fortress Biotech, Inc. traded at a price-to-earnings ratio of about 15.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S and dividend yield have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.